FeesSafety
Pluang+

EyePoint Pharma shares plunge 80% after Phase 3 trial failure for DURAVYU in eye disease

Market News
20 Oct 2026, 00:58 WIB
PRNewsWire
View Source
Bearish
EyePoint Pharma shares plunge 80% after Phase 3 trial failure for DURAVYU in eye disease

EyePoint Pharmaceuticals' stock dropped nearly 80% after its Phase 3 LUCIA trial for DURAVYU in wet age-related macular degeneration failed to meet the primary endpoint of non-inferiority to the control drug aflibercept. Despite missing this key goal, DURAVYU showed benefits like a 38% reduction in treatment burden. Legal firm Levi & Korsinsky is investigating potential securities law violations and encouraging affected investors to submit loss information for possible compensation. Investors who bought shares at inflated prices before the trial results may have legal rights, but no court appearances are required to participate in the investigation.

EyePoint Pharmaceuticals' recent trial results provide context for readers interested in health-sector stocks. For readers following this sector, here is Pluang's market snapshot as of Oct 20, 2026 04:11 WIB: out of 150 priced health-sector US stocks, 84 rose and 65 fell today. Among notable movers, Hinge Health Inc. (HNGE) rose 4.84% to USD 103.96 with a typical hold time of 5 days, Relay Therapeutics Inc. (RLAY) increased 4.79% to USD 17.06 with a 10-day hold, and DENTSPLY SIRONA Inc. (XRAY) gained 4.74% to USD 8.84 with a much longer typical hold time of 73 days.

More News

Asia-Pacific companion animal diagnostics market to hit $1.65B by 2031 with 10.2% CAGR driven by AI and pet care trends

Asia-Pacific companion animal diagnostics market to hit $1.65B by 2031 with 10.2% CAGR driven by AI and pet care trends

The Asia-Pacific companion animal diagnostics market is projected to grow from $840 million in 2024 to $1.65 billion by 2031, at a CAGR of 10.2%. Growth is fueled by rising pet ownership, increased awareness of animal health, and advances in veterina...

Market News
Bullish
48 minutes ago
Global multi-omics market to grow to $28.6B by 2036, driven by AI and precision medicine advances

Global multi-omics market to grow to $28.6B by 2036, driven by AI and precision medicine advances

The global multi-omics market, valued at $8.6 billion in 2025, is projected to reach $28.6 billion by 2036 with a CAGR of 10.6%. Growth is fueled by advances in AI, precision medicine, sequencing technologies, and increased investment in drug discove...

Market News
Bullish
49 minutes ago
Longevity tech market to hit $44.18B by 2036, driven by AI, regenerative medicine, and aging biology advances

Longevity tech market to hit $44.18B by 2036, driven by AI, regenerative medicine, and aging biology advances

The global longevity technologies market is projected to grow from $9.64 billion in 2026 to $44.18 billion by 2036, at a CAGR of 16.4%. Growth is fueled by advances in AI-driven drug discovery, regenerative medicine, biomarker diagnostics, and a deep...

Market News
Bullish
50 minutes ago
Global induction furnaces market to reach $4.2B by 2036, driven by green tech and AI innovations.

Global induction furnaces market to reach $4.2B by 2036, driven by green tech and AI innovations.

The global induction furnaces market, valued at $2.4 billion in 2025, is projected to grow to $4.2 billion by 2036 with a 5.2% CAGR. Growth is fueled by industrial electrification, decarbonization efforts, metal recycling, and advances in energy-effi...

Market News
Bullish
51 minutes ago
Global smart inhalers market to reach $6.8B by 2036, driven by rising respiratory diseases and digital health tech.

Global smart inhalers market to reach $6.8B by 2036, driven by rising respiratory diseases and digital health tech.

The global smart inhalers market is projected to grow from $1.9 billion in 2026 to $6.8 billion by 2036, at a CAGR of 13.6%. Growth is fueled by increasing cases of asthma, COPD, and other respiratory diseases, alongside the adoption of digital healt...

Market News
Bullish
52 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App